Two human challenge studies on a new malaria drug have yielded promising data about safety and dosage.
The vaccine uses whole, live weakened early versions of the most common form of malaria.
The vaccine is being developed on behalf of the US Department of Defense as part of its countermeasure portfolio against bioterrorism agents.
This month, South Korea needed emergency vaccine imports after outbreaks of the disease.
Researchers showed that a new reactive vaccination strategy for foot-and-mouth disease outbreaks can achieve significant cost savings by identifying vaccination capacity.
In a clinical trial, researchers demonstrated that a new vaccine for malaria was up to 100 percent effective at 10 weeks after the last dose of vaccine.
The research could be used to inform decisions on how malaria vaccines are deployed or modified.
A new study reveals an antidote that worked in mice days after exposure.
Cattle farms in Jeongeup, North Jeolla Province, and Boeun County, North Chungcheong Province, where foot-and-mouth disease infections have been found have antibody formation rates of five and 19 percent despite mandatory vaccination.
A drug used to treat malaria patients in the United Kingdom has failed for the first time.